Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 34

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 34
---
 us that later prove to be material. If any of these risks occur, our business, operating results and financial condition could be seriously harmed, the trading price of our common stock could decline, and you could lose some or all of your investment.

Risks Related to this Offering and Ownership of our Securities

Future sales by stockholders, or the perception that such sales may occur, may depress the price of our common stock.

The sale or availability for sale of substantial
amounts of our shares in the public market or exercise of common stock warrants and options or settlement of restricted stock units, or
the perception that such sales could occur, could adversely affect the market price of our common stock and also could impair our ability
to raise capital through future offerings of our shares. As of February 5, 2025, we had 5,861,054 outstanding shares of common stock.
Any decline in the price of our common stock may encourage short sales, which could place further downward pressure on the price of our
common stock and may impair our ability to raise additional capital through the sale of equity securities.

The issuance of shares upon exercise of derivative securities may cause immediate and substantial dilution to our existing stockholders.

The issuance of shares upon exercise of options
and settlement of outstanding restricted stock units may result in substantial dilution to the interests of other stockholders since these
selling stockholders may ultimately convert or exercise and sell all or a portion of the full amount issuable upon exercise. If all derivative
securities outstanding as of February 5, 2025, were converted or exercised into shares of common stock, there would be approximately an
additional 8,108,088 shares of common stock outstanding as a result. The issuance of these shares will have the effect of further diluting
the proportionate equity interest and voting power of holders of our common stock.

Since we have broad discretion in how we use the proceeds from this offering, we may use the proceeds in ways in which you disagree.

Our management will have significant flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for our company. The failure of our management to use such funds effectively could have a material adverse effect on our business